The overview of systematic reviews indicates that stem cell therapy significantly improves clinical remission and fistula closure rates. The relative risk for clinical remission was 1.299, and for short- and long-term closure rates, it was 1.481 and 1.422, respectively. Importantly, safety analysis revealed no significant increase in adverse events, suggesting a favorable safety profile. The results recommend further high-quality studies to solidify these findings and potentially integrate stem cell therapy into standard fistula management practices.
Journal Article by Tripathi T, Mohan S (…) Balaraman AK et 22 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.